176 related articles for article (PubMed ID: 37559436)
1. Third generation quinoline-3-carboxamide transcriptional disrupter of HDAC4, HIF-1α, and MEF-2 signaling for metastatic castration-resistant prostate cancer.
Isaacs JT; Dalrymple SL; Antony L; Marc Rosen D; Coleman IM; Nelson PS; Kostova M; Murray IA; Perdew GH; Denmeade SR; Akinboye ES; Brennen WN
Prostate; 2023 Nov; 83(15):1470-1493. PubMed ID: 37559436
[TBL] [Abstract][Full Text] [Related]
2. Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment.
Isaacs JT; Antony L; Dalrymple SL; Brennen WN; Gerber S; Hammers H; Wissing M; Kachhap S; Luo J; Xing L; Björk P; Olsson A; Björk A; Leanderson T
Cancer Res; 2013 Feb; 73(4):1386-99. PubMed ID: 23149916
[TBL] [Abstract][Full Text] [Related]
3. Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironment.
Isaacs JT; Dalrymple SL; Rosen DM; Hammers H; Olsson A; Leanderson T
Oncotarget; 2014 Sep; 5(18):8093-106. PubMed ID: 25193858
[TBL] [Abstract][Full Text] [Related]
4. Assessment of the bone scan index in a randomized placebo-controlled trial of tasquinimod in men with metastatic castration-resistant prostate cancer (mCRPC).
Armstrong AJ; Kaboteh R; Carducci MA; Damber JE; Stadler WM; Hansen M; Edenbrandt L; Forsberg G; Nordle Ö; Pili R; Morris MJ
Urol Oncol; 2014 Nov; 32(8):1308-16. PubMed ID: 25240761
[TBL] [Abstract][Full Text] [Related]
5. Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1α-mediated regulation of apoptosis and autophagy.
Zhang X; Qi Z; Yin H; Yang G
Theranostics; 2019; 9(4):1096-1114. PubMed ID: 30867818
[TBL] [Abstract][Full Text] [Related]
6. Nucleus accumbens-associated protein-1 promotes glycolysis and survival of hypoxic tumor cells via the HDAC4-HIF-1α axis.
Zhang Y; Ren YJ; Guo LC; Ji C; Hu J; Zhang HH; Xu QH; Zhu WD; Ming ZJ; Yuan YS; Ren X; Song J; Yang JM
Oncogene; 2017 Jul; 36(29):4171-4181. PubMed ID: 28319066
[TBL] [Abstract][Full Text] [Related]
7. Tasquinimod inhibits prostate cancer growth in bone through alterations in the bone microenvironment.
Magnusson LU; Hagberg Thulin M; Plas P; Olsson A; Damber JE; Welén K
Prostate; 2016 Mar; 76(4):383-93. PubMed ID: 26660725
[TBL] [Abstract][Full Text] [Related]
8. Suppression of TRPM7 Inhibited Hypoxia-Induced Migration and Invasion of Androgen-Independent Prostate Cancer Cells by Enhancing RACK1-Mediated Degradation of HIF-1
Yang F; Cai J; Zhan H; Situ J; Li W; Mao Y; Luo Y
Oxid Med Cell Longev; 2020; 2020():6724810. PubMed ID: 32215176
[TBL] [Abstract][Full Text] [Related]
9. Phase II randomized, double-blind, placebo-controlled study of tasquinimod in men with minimally symptomatic metastatic castrate-resistant prostate cancer.
Pili R; Häggman M; Stadler WM; Gingrich JR; Assikis VJ; Björk A; Nordle O; Forsberg G; Carducci MA; Armstrong AJ
J Clin Oncol; 2011 Oct; 29(30):4022-8. PubMed ID: 21931019
[TBL] [Abstract][Full Text] [Related]
10. HDAC4 promotes nasopharyngeal carcinoma progression and serves as a therapeutic target.
Cheng C; Yang J; Li SW; Huang G; Li C; Min WP; Sang Y
Cell Death Dis; 2021 Feb; 12(2):137. PubMed ID: 33542203
[TBL] [Abstract][Full Text] [Related]
11. [Tasquinimod: How to act on microenvironment in metastatic prostate cancer].
Houédé N; Irani J
Prog Urol; 2015 May; 25(6):298-305. PubMed ID: 25684391
[TBL] [Abstract][Full Text] [Related]
12. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors.
Olsson A; Björk A; Vallon-Christersson J; Isaacs JT; Leanderson T
Mol Cancer; 2010 May; 9():107. PubMed ID: 20470445
[TBL] [Abstract][Full Text] [Related]
13. Validation of histone deacetylase 3 as a therapeutic target in castration-resistant prostate cancer.
McLeod AB; Stice JP; Wardell SE; Alley HM; Chang CY; McDonnell DP
Prostate; 2018 Mar; 78(4):266-277. PubMed ID: 29243324
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional activation of hypoxia-inducible factor-1alpha by HDAC4 and HDAC5 involves differential recruitment of p300 and FIH-1.
Seo HW; Kim EJ; Na H; Lee MO
FEBS Lett; 2009 Jan; 583(1):55-60. PubMed ID: 19071119
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol inhibits hypoxia-inducible factor-1α-mediated androgen receptor signaling and represses tumor progression in castration-resistant prostate cancer.
Mitani T; Harada N; Tanimori S; Nakano Y; Inui H; Yamaji R
J Nutr Sci Vitaminol (Tokyo); 2014; 60(4):276-82. PubMed ID: 25297617
[TBL] [Abstract][Full Text] [Related]
16. HDAC4 protein regulates HIF1α protein lysine acetylation and cancer cell response to hypoxia.
Geng H; Harvey CT; Pittsenbarger J; Liu Q; Beer TM; Xue C; Qian DZ
J Biol Chem; 2011 Nov; 286(44):38095-38102. PubMed ID: 21917920
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of metastasis in a castration resistant prostate cancer model by the quinoline-3-carboxamide tasquinimod (ABR-215050).
Jennbacken K; Welén K; Olsson A; Axelsson B; Törngren M; Damber JE; Leanderson T
Prostate; 2012 Jun; 72(8):913-24. PubMed ID: 22287276
[TBL] [Abstract][Full Text] [Related]
18. Corosolic acid, a natural triterpenoid, induces ER stress-dependent apoptosis in human castration resistant prostate cancer cells via activation of IRE-1/JNK, PERK/CHOP and TRIB3.
Ma B; Zhang H; Wang Y; Zhao A; Zhu Z; Bao X; Sun Y; Li L; Zhang Q
J Exp Clin Cancer Res; 2018 Sep; 37(1):210. PubMed ID: 30176898
[TBL] [Abstract][Full Text] [Related]
19. HDAC inhibition impedes epithelial-mesenchymal plasticity and suppresses metastatic, castration-resistant prostate cancer.
Ruscetti M; Dadashian EL; Guo W; Quach B; Mulholland DJ; Park JW; Tran LM; Kobayashi N; Bianchi-Frias D; Xing Y; Nelson PS; Wu H
Oncogene; 2016 Jul; 35(29):3781-95. PubMed ID: 26640144
[TBL] [Abstract][Full Text] [Related]
20. A review of tasquinimod in the treatment of advanced prostate cancer.
Williamson SC; Hartley AE; Heer R
Drug Des Devel Ther; 2013; 7():167-74. PubMed ID: 23662046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
